Rituximab vs placeboQuality of life · thyroid‐associated ophthalmopathy1 finding from 1 reviewRituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 25 participantsVery low
Rituximab vs intravenous methylprednisoloneQuality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy1 finding from 1 reviewRituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 27 participantsVery low